why choose us

First received: May 18, 2023

Clinical Trial: Pimavanserin and Aggression and Social Cognition.

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Intermittent Explosive Disorder

Study Type: INTERVENTIONAL


Official Title: Effect of Pimavanserin on Aggression and Social Cognition.

Brief Summary: The investigators are studying how certain drugs can reduce anger outbursts in people with anger problems.In this study the investigators seek to determine if a single 34 mg (two 17 mg tablets) oral dose of the 5-HT2a receptor blocker, pimavanserin, will reduce aggressive responding in individuals with impulsive aggression (Intermittent Explosive Disorder: IED) on a laboratory task that assesses aggression (Taylor Aggression Paradigm: TAP).We will also be examining how this drug impacts hostile social cognition…

Read more